Options of Chemotherapy in the Treatment of Prostate Cancer
Authors:
I. Richter 1,2; J. Dvořák 2; J. Bartoš 1
Authors‘ workplace:
Onkologické oddělení, Krajská nemocnice Liberec, a. s.
1; Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
2
Published in:
Klin Onkol 2017; 30(1): 28-33
Category:
Review
doi:
https://doi.org/10.14735/amko201728
Overview
Background:
Prostate cancer is one of the most common malignancies in men. Chemotherapy has an important role in the management of prostate cancer, especially for the treatment of castrate resistant prostate cancer (mCRPC). According to recently published studies, chemotherapy can also be used to treat advanced hormone sensitive disease.
Aim:
The aim of this report is to review the currently available options for chemotherapy of prostate cancer.
Results:
Docetaxel is a chemotherapeutic agent used for standard treatment of mCRPC as 1st line therapy. In TAX 327 and SWOG 9916 studies reported in 2004, docetaxel, the first cytostatic agent indicated for this disease, prolonged overall survival. As a 2nd line mCRPC treatment, kabazitaxel resulted in longer overall survival than mitoxantrone, according to the results of the TROPIC study. Targeted hormone treatment, radium-223 irradiation, and immunotherapy are other treatment options for patients with mCRPC. Currently, the main focus is to develop an optimal sequence of treatments. Standard androgen deprivation therapy (ADT) is the standard option for patients with advanced hormone sensitive prostate cancer. According to recently published studies (CHAARTED, STAMPEDE), docetaxel with ADT increases overall survival in this group of patients. In the Czech Republic, this option is still off-label. Chemotherapy is not indicated in patients with early prostate cancer after radical prostatectomy or radiotherapy.
Key words:
prostate cancer – metastasis – chemotherapy – docetaxel – cabazitaxel
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
9. 5. 2016
Accepted:
6. 6. 2016
Sources
1. Ondrušová M, Mužík J, Kliment J et al. Prostate cancer incidence and mortality in selected countries of central Europe. Klin Onkol 2011; 24 (2): 126–132.
2. Mottet N, Bellmunt J, van den Bergh RC et al. EAU Guidelines on prostate cancer – update April 2014. Arnhem: European Association of Urology 2014: 172.
3. Katolická J. Chemoterapie v léčbě kastračně rezistentního karcinomu prostaty. Urol Prax 2014; 15: 120–122.
4. Ondruš D, Ondrušová M. Manažement pacientov s kastračne rezistentným metastatickým karcinómom prostaty. Klin Onkol 2015; 28 (1): 24–29. doi: 10.14735/ amko24.
5. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trila with palliative end points. J Clin Oncol 1996; 14 (6): 1756–1764.
6. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–1512.
7. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone plus prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513–1520.
8. Kellokumpu-Lehtinen PL, Harmenberrg U, Joensuu T et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randimised, phase 3 trial. Lancet Oncol 2013; 14 (2): 117–124. doi: 10.1016/S1470-2045 (12) 70537-5.
9. Millikan RE. Chemotherapy of advanced prostatic carcinoma. Semin Oncol 1999; 26 (2): 185–191.
10. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednison and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27 (32): 5431–5438. doi: 10.1200/JCO.2008.20.1228.
11. Zampino MG, Verri E, Locatelli M et al. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. Anticancer Res 2006; 26 (3B): 2375–2380.
12. Matoušková M, Katolická J, Hanuš M et al. Chemoterapie II. linie CRCP-vinorelbin + hydrokortizon – prospektivní multicentrická studie. Ces Urol 2012; 16 (Suppl 1): 74.
13. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostatae cancer progressing after docetaxel treatment: a randimised open-label trial. Lancet 2010; 376 (9747): 1147–1154. doi: 10.1016/S0140-6736 (10) 61389-X.
14. Bahl A, Oudard S, Tombal B et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013; 24 (9): 2402–2408. doi: 10.1093/annonc/mdt194.
15. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24 (10): 1633–1642.
16. Tsao CK, Cutting E, Martin J et al. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol 2014; 6 (3): 97–104. doi: 10.1177/1756287214528557.
17. Heidenreich A, Bracarda S, Mason M et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer 2014; 50 (6): 1090–1099. doi: 10.1016/j.ejca.2014.01.006.
18. Mita AC, Denis LJ, Rowinski EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15 (2): 723–730. doi: 10.1158/1078-0432.CCR-08-0596.
19. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187–1197.
20. de Bono JS, Logothesis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995–2005. doi: 10.1056/NEJMoa1014618.
21. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213–223. doi: 10.1056/NEJMoa1213755.
22. Ryan CJ, Smith MR, de Bono JS et al. Abirateron in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (2): 138–148. doi: 10.1056/NEJMoa1209096.
23. Beer TM, Amstrong AJ, Rathkof DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371 (5): 424–433. doi: 10.1056/NEJMoa1405095.
24. Pezaro CJ, Le Moulec S, Albiges L et al. Response to cabazitaxel in CRPC patients previously treated with docetaxel and abirateron acetate. J Clin Oncol 2013; 31 (Suppl 6): abstr. 155.
25. Wissing MD, Coenen JL, Van den Berg P et al. A retrospective study on cabazitaxel and abirateron acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients. Eur Cancer Congr 2013; abstr. 2904.
26. Mezynski J, Pezaro C, Bianchini D et al. Antitumour aktivity of docetaxel following treatment with the CYP17A1 inhibitor abirateron: clinical evidence for cross-resistence? Ann Oncol 2012; 23 (11): 2943–1947. doi: 10.1093/annonc/mds119.
27. Darshan MS, Loftus MS, Thadani-Mulero M et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical response in metastatic prostate cancer. Cancer Res 2011; 71 (18): 6019–6029. doi: 10.1158/0008-5472.CAN-11-1417.
28. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rew Cancer 2004; 4 (4): 253–265.
29. Moos PJ, Fritzpatrick FA. Taxane propagate apoptosis via two cell populations with distinctive cytological traits. Cell Growth Differ 1998; 9 (8): 687–697.
30. Li Y, Li X, Hussain M et al. Regulation of mikrotubul, apoptosis, and cell cycle-related genes by Taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004; 6 (2): 158–167.
31. van Soest RJ, van Royen ME, de Morree ES et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamid may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49 (18): 3821–3830. doi: 10.1016/j.ejca.2013.09.026.
32. Poon DM, Ng J, Chan K. Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration resistant prostate cancer. Prostate Inter 2015; 3 (2): 51–55. doi: 10.1016/j.prnil.2015.03.002.
33. Caffo O, Pappagallo G, Brugnara S et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assesment of clinical outcomes and predictive factors. Urology 2012; 79 (3): 644–649. doi: 10.1016/j.urology.2011.11.043.
34. Oudard S, Kramer G, Caffo O et al. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int 2015; 115 (5): 744–752. doi: 10.1111/bju.12845.
35. Loriot Y, Massard C, Gross-Goupil M et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010; 46 (10): 1770–1772. doi: 10.1016/j.ejca.2010.04.010.
36. Petrioli R, Francini E, Roviello G et al. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 2015; 6 (5): 99–103. doi: 10.5306/wjco.v6.i5.99.
37. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14 (2): 149–158. doi: 10.1016/S1470-2045 (12) 70560-0.
38. Gravis G, Boher JM, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analys sof the randomised phase 3 GETUG-AFU trial. Eur Urol 2015; 70 (2): 256–262. doi: 10.1016/j.eururo.2015.11.005.
39. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373 (8): 737–746. doi: 10.1056/NEJMoa1503747.
40. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zolendronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomised controlled trial. Lancet 2016; 387 (10024): 1163–1177. doi: 10.1016/S0140-6736 (15) 01037-5.
41. Tucci M, Bertaglia V, Vignani F et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systemic review and meta-analysis. Eur Urol 2016; 69 (4): 563–573. doi: 10.1016/j.eururo.2015.09.013.
42. Rosenthal SA, Hunt D, Sartor AO et al. A phase 3 trial of 2 years od androgen suppression and radiation therapy with or without adjutant chemotherapy for high-risk prostate cancer: final results of Radiation therapy oncology group phase III ransomised trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys 2015; 93 (2): 294–302. doi: 10.1016/j.ijrobp.2015.05.024.
43. Fizazi K, Faivre L, Lesaunier F et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015; 16 (7): 787–794. doi: 10.1016/S1470-2045 (15) 00011-X.
44. Sandler HM, Hu C, Rosenthal SA et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015; 33 (Suppl): abstr. 5002.
45. Dorff TB, Flaig TW, Tangen CM et al. Adjuvant androgen deprivation of high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29 (15): 2040–2045. doi: 10.1200/JCO.2010.32. 2776.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
![Issue 1](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/cbde62fec73c51928785059021bba067.jpeg)
2017 Issue 1
Most read in this issue
- Lymphoedema Following Regional Lymph Node Surgery for Breast Cancer
- Epithelial-mesenchymal Transition in Tumor Tissue and Its Role for Metastatic Spread of Cancer
- Options of Chemotherapy in the Treatment of Prostate Cancer
- Daratumumab – Hope for Myeloma Patients, a Challenge for Clinical Laboratories